Cargando…
Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats
BACKGROUND: Osteoporosis is a systemic skeletal disorder and occurs frequently in postmenopausal women and older men. This study aimed to examine whether diosmetin (DIO) can relieve estrogen deficiency—induced osteoporosis and to explore the underlying mechanisms of this potential effect. METHODS: F...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661890/ https://www.ncbi.nlm.nih.gov/pubmed/33209892 http://dx.doi.org/10.21037/atm-20-6309 |
_version_ | 1783609290826711040 |
---|---|
author | Hu, Song Huang, Youyi Chen, Yong Zhou, Renyi Yang, Xiaozhong Zou, Yi Gao, Daxin Huang, Hua Yu, Dongming |
author_facet | Hu, Song Huang, Youyi Chen, Yong Zhou, Renyi Yang, Xiaozhong Zou, Yi Gao, Daxin Huang, Hua Yu, Dongming |
author_sort | Hu, Song |
collection | PubMed |
description | BACKGROUND: Osteoporosis is a systemic skeletal disorder and occurs frequently in postmenopausal women and older men. This study aimed to examine whether diosmetin (DIO) can relieve estrogen deficiency—induced osteoporosis and to explore the underlying mechanisms of this potential effect. METHODS: Forty-nine Sprague-Dawley (SD) rats were divided into seven groups. Six groups underwent bilateral ovariectomy (OVX), while the sham group underwent ovarian exposure surgery. DIO and evodiamine were administered 3 days before surgery, and then subcutaneously every 3 days for 3 months in the following fashion: group I, DIO (100 mg/kg); group II, OVX; group III, OVX + DIO (50 mg/kg); group IV, OVX + DIO (100 mg/kg); group V, OVX + evodiamine (10 mg/kg) group; group VI, OVX + DIO (100 mg/kg) + evodiamine (10 mg/kg) group. Bone histopathological damage, bone loss, osteoclast production, and the expression level of transient receptor potential vanilloid 1 (TRPV1) were detected. RESULTS: Compared with the sham group, the expression of bone resorption–related genes, osteoclast-associated receptor (OSCAR) (1.00%±0.16% versus 4.5%±0.28%, **, P<0.01) and tartrate-resistant acid phosphatase (TRAP) (2.0%±0.6% versus 18.00±1.2%, ***, P<0.001), was increased significantly. The protein level of osteogenic marker proteins, osterix (Osx) (1.0%±0.1% versus 0.03%±0.01%, **, P<0.01) and type 1 collagen (COL1A1) (1.0%±0.13% versus 0.13%±0.05%, **, P<0.01) was decreased significantly with the increase of TRPV1 (1.0%±0.15% versus 2.89%±0.28%, **, P<0.01) protein level. Notably, DIO can alleviate some abnormal symptoms related to osteoporosis. CONCLUSIONS: DIO can relieve typical osteoporosis symptoms in an OVX osteoporosis rat model. The underlying mechanism may be associated with the downregulation of TRPV1. |
format | Online Article Text |
id | pubmed-7661890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-76618902020-11-17 Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats Hu, Song Huang, Youyi Chen, Yong Zhou, Renyi Yang, Xiaozhong Zou, Yi Gao, Daxin Huang, Hua Yu, Dongming Ann Transl Med Original Article BACKGROUND: Osteoporosis is a systemic skeletal disorder and occurs frequently in postmenopausal women and older men. This study aimed to examine whether diosmetin (DIO) can relieve estrogen deficiency—induced osteoporosis and to explore the underlying mechanisms of this potential effect. METHODS: Forty-nine Sprague-Dawley (SD) rats were divided into seven groups. Six groups underwent bilateral ovariectomy (OVX), while the sham group underwent ovarian exposure surgery. DIO and evodiamine were administered 3 days before surgery, and then subcutaneously every 3 days for 3 months in the following fashion: group I, DIO (100 mg/kg); group II, OVX; group III, OVX + DIO (50 mg/kg); group IV, OVX + DIO (100 mg/kg); group V, OVX + evodiamine (10 mg/kg) group; group VI, OVX + DIO (100 mg/kg) + evodiamine (10 mg/kg) group. Bone histopathological damage, bone loss, osteoclast production, and the expression level of transient receptor potential vanilloid 1 (TRPV1) were detected. RESULTS: Compared with the sham group, the expression of bone resorption–related genes, osteoclast-associated receptor (OSCAR) (1.00%±0.16% versus 4.5%±0.28%, **, P<0.01) and tartrate-resistant acid phosphatase (TRAP) (2.0%±0.6% versus 18.00±1.2%, ***, P<0.001), was increased significantly. The protein level of osteogenic marker proteins, osterix (Osx) (1.0%±0.1% versus 0.03%±0.01%, **, P<0.01) and type 1 collagen (COL1A1) (1.0%±0.13% versus 0.13%±0.05%, **, P<0.01) was decreased significantly with the increase of TRPV1 (1.0%±0.15% versus 2.89%±0.28%, **, P<0.01) protein level. Notably, DIO can alleviate some abnormal symptoms related to osteoporosis. CONCLUSIONS: DIO can relieve typical osteoporosis symptoms in an OVX osteoporosis rat model. The underlying mechanism may be associated with the downregulation of TRPV1. AME Publishing Company 2020-10 /pmc/articles/PMC7661890/ /pubmed/33209892 http://dx.doi.org/10.21037/atm-20-6309 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Hu, Song Huang, Youyi Chen, Yong Zhou, Renyi Yang, Xiaozhong Zou, Yi Gao, Daxin Huang, Hua Yu, Dongming Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats |
title | Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats |
title_full | Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats |
title_fullStr | Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats |
title_full_unstemmed | Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats |
title_short | Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats |
title_sort | diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of trpv1 in osteoporosis rats |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661890/ https://www.ncbi.nlm.nih.gov/pubmed/33209892 http://dx.doi.org/10.21037/atm-20-6309 |
work_keys_str_mv | AT husong diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT huangyouyi diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT chenyong diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT zhourenyi diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT yangxiaozhong diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT zouyi diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT gaodaxin diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT huanghua diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats AT yudongming diosmetinreducesbonelossandosteoclastogenesisbyregulatingtheexpressionoftrpv1inosteoporosisrats |